{"transactions":[{"id":2210640,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO & Managing Director E"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-07-07T21:17:07.000Z","date":"2022-07-05","kind":"exercise","acquired":false,"shares":4032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC (\"GW\") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the \"Merger\"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger."}],"balance_after":4031,"derivative":{"exercise_price":0.02,"expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":4032},"source":{"system":"sec-edgar","filing":"0001765581-22-000069","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558122000069/edgardoc.xml","form_type":"4"}},{"id":2210639,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO & Managing Director E"}}],"security":"Ordinary Shares","published_at":"2022-07-07T21:17:07.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":1177,"price":160,"value":188320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":14663,"source":{"system":"sec-edgar","filing":"0001765581-22-000069","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558122000069/edgardoc.xml","form_type":"4"}},{"id":2210638,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO & Managing Director E"}}],"security":"Ordinary Shares","published_at":"2022-07-07T21:17:07.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":4032,"price":160,"value":645120.0,"ownership":{"direct":true},"balance_after":15840,"source":{"system":"sec-edgar","filing":"0001765581-22-000069","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558122000069/edgardoc.xml","form_type":"4"}},{"id":2210637,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO & Managing Director E"}}],"security":"Ordinary Shares","published_at":"2022-07-07T21:17:07.000Z","date":"2022-07-05","kind":"exercise","acquired":true,"shares":4032,"price":0.02,"value":80.64,"ownership":{"direct":true},"balance_after":19872,"source":{"system":"sec-edgar","filing":"0001765581-22-000069","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558122000069/edgardoc.xml","form_type":"4"}},{"id":2277410,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, COO & Managing Director E"}}],"security":"Ordinary Shares","published_at":"2022-05-10T01:46:17.000Z","date":"2022-05-05","kind":"tax_withholding","acquired":false,"shares":1096,"price":153.22,"value":167929.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units."}],"balance_after":15840,"source":{"system":"sec-edgar","filing":"0001765581-22-000043","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558122000043/edgardoc.xml","form_type":"4"}},{"id":2341471,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-09T23:08:10.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":7820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2022, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":16936,"source":{"system":"sec-edgar","filing":"0001765581-22-000032","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558122000032/edgardoc.xml","form_type":"4"}},{"id":2722754,"issuer":{"id":818,"kind":"organization","name":"Jazz Pharmaceuticals plc","symbol":"JAZZ"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP COO & Managing Dir EUR/INT"}}],"security":"Ordinary Shares","published_at":"2021-05-07T20:46:03.000Z","date":"2021-05-05","kind":"grant","acquired":true,"shares":9091,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of May 5, 2021, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years."}],"balance_after":9116,"source":{"system":"sec-edgar","filing":"0001765581-21-000057","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1232524/000176558121000057/edgardoc.xml","form_type":"4"}},{"id":2722909,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":42192,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":42192},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722908,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":67440,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":67440},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722907,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":82224,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2030-06-04","underlying":"Ordinary Shares","underlying_shares":82224},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722906,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":137016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2030-06-04","underlying":"Ordinary Shares","underlying_shares":137016},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722905,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":17964,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":17964},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722904,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":79812,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":79812},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722903,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":42048,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":14.3342,"expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":42048},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722902,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":17904,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":17904},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722901,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":119340,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":119340},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722900,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":58884,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":9.6092,"expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":58884},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722899,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":6468,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":0.0017,"expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":6468},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722898,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":52560,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the \"Transaction Agreement\"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration."}],"balance_after":0,"derivative":{"exercise_price":9.8117,"expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":52560},"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2722897,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2021-05-07T16:25:12.000Z","date":"2021-05-05","kind":"disposition_to_issuer","acquired":false,"shares":2496,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland (\"Jazz\"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz (\"Bidco\") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\") (continued in footnote 2)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz (\"Jazz ordinary shares\"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-018673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321018673/doc4.xml","form_type":"4"}},{"id":2835509,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-02-24T18:44:14.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":42192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on February 22, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":42192,"derivative":{"exercise_price":0.0014,"expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":42192},"source":{"system":"sec-edgar","filing":"0000899243-21-008084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321008084/doc4.xml","form_type":"4"}},{"id":2835508,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2021-02-24T18:44:14.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":67440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest on February 22, 2024 if certain performance conditions are satisfied."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc."}],"balance_after":67440,"derivative":{"exercise_price":0.0014,"exercise_date":"2024-02-22","expiration_date":"2031-02-22","underlying":"Ordinary Shares","underlying_shares":67440},"source":{"system":"sec-edgar","filing":"0000899243-21-008084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924321008084/doc4.xml","form_type":"4"}},{"id":2960485,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-12-01","kind":"exercise","acquired":false,"shares":28560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.34 U.S. Dollars as of December 1, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-01-06","expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":28560},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960484,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":5988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":5988},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960483,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":8952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-02-26","expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":8952},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960482,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":57684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":28560,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-01-06","expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":57684},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960481,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":6468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-01-06","expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":6468},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960480,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":10452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":5,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":10452},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960479,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":false,"shares":3924,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."}],"balance_after":6,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-06-24","expiration_date":"2025-06-24","underlying":"Ordinary Shares","underlying_shares":3924},"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960478,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":9060,"price":11.79,"value":106817.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($141.5258 per ADS). These shares were sold in multiple transactions at prices ranging from $141.40 per ADS (or $11.78 per ordinary share) to $142.00 per ADS (or $11.83 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2496,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960477,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":19500,"price":11.74,"value":228930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.8760 per ADS). These shares were sold in multiple transactions at prices ranging from $140.40 per ADS (or $11.78 per ordinary share) to $141.31 per ADS (or $11.78 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"}],"balance_after":11556,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960476,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-12-01","kind":"exercise","acquired":true,"shares":28560,"price":0.0013,"value":37.128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.34 U.S. Dollars as of December 1, 2020."}],"balance_after":31056,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960475,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"sale","acquired":false,"shares":93468,"price":11.67,"value":1090771.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2020."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represented by ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($140.0338 per ADS). These shares were sold in multiple transactions at prices ranging from $140.00 per ADS (or $11.66 per ordinary share) to $140.25 per ADS (or $11.69 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"}],"balance_after":2496,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960474,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":5988,"price":0.0013,"value":7.7844,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."}],"balance_after":95964,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960473,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":8952,"price":0.0013,"value":11.6376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."}],"balance_after":89976,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960472,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":57684,"price":0.0013,"value":74.9892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."}],"balance_after":81024,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960471,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":6468,"price":0.0013,"value":8.4084,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."}],"balance_after":23340,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960470,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":10452,"price":0.0013,"value":13.5876,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."}],"balance_after":16872,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":2960469,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2020-12-02T21:00:09.000Z","date":"2020-11-30","kind":"exercise","acquired":true,"shares":3924,"price":0.0013,"value":5.1012,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 30, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Reflects an adjustment to total holdings to exclude seven shares incorrectly included in prior reports."}],"balance_after":6420,"source":{"system":"sec-edgar","filing":"0000899243-20-032605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320032605/doc4.xml","form_type":"4"}},{"id":3118519,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2020-06-08T20:03:05.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":82224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These share options will vest in four equal annual installments beginning on June 4, 2021."}],"balance_after":82224,"derivative":{"exercise_price":0.0013,"expiration_date":"2030-06-04","underlying":"Ordinary Shares","underlying_shares":82224},"source":{"system":"sec-edgar","filing":"0000899243-20-015694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320015694/doc4.xml","form_type":"4"}},{"id":3118518,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Share Options","published_at":"2020-06-08T20:03:05.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":137016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest on June 4, 2023 if certain performance conditions are satisfied."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest on June 4, 2023 if certain performance conditions are satisfied."}],"balance_after":137016,"derivative":{"exercise_price":0.0013,"expiration_date":"2030-06-04","underlying":"Ordinary Shares","underlying_shares":137016},"source":{"system":"sec-edgar","filing":"0000899243-20-015694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924320015694/doc4.xml","form_type":"4"}},{"id":3500324,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-06-05T20:00:20.000Z","date":"2019-06-03","kind":"exercise","acquired":false,"shares":64800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 3, 2019."}],"balance_after":0,"derivative":{"exercise_price":3.24,"exercise_date":"2019-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":64800},"source":{"system":"sec-edgar","filing":"0000899243-19-015678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015678/doc4.xml","form_type":"4"}},{"id":3500323,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-05T20:00:20.000Z","date":"2019-06-03","kind":"sale","acquired":false,"shares":64800,"price":14.61,"value":946728.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price per ordinary share ($175.35 per ADS). These shares were sold in multiple transactions at prices ranging from $175.04 per ADS (or $14.59 per ordinary share) to $175.64 per ADS (or $14.64 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2503,"source":{"system":"sec-edgar","filing":"0000899243-19-015678","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015678/doc4.xml","form_type":"4"}},{"id":3500322,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-05T20:00:20.000Z","date":"2019-06-03","kind":"exercise","acquired":true,"shares":64800,"price":3.24,"value":209952.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 3, 2019."}],"balance_after":67303,"source":{"system":"sec-edgar","filing":"0000899243-19-015678","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319015678/doc4.xml","form_type":"4"}},{"id":3520528,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-17T19:00:31.000Z","date":"2019-05-15","kind":"exercise","acquired":false,"shares":1200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of May 15, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The balance has been reduced to adjust for an overstatement of 1,000 shares in the reporting person's form 4 filed on May 9, 2019."}],"balance_after":64800,"derivative":{"exercise_price":3.29,"exercise_date":"2019-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0000899243-19-014050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319014050/doc4.xml","form_type":"4"}},{"id":3520527,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2019-05-17T19:00:31.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":1200,"price":15.01,"value":18012.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The exercise price reported is price per ordinary share converted from price per ADS."}],"balance_after":2503,"source":{"system":"sec-edgar","filing":"0000899243-19-014050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319014050/doc4.xml","form_type":"4"}},{"id":3520526,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2019-05-17T19:00:31.000Z","date":"2019-05-15","kind":"exercise","acquired":true,"shares":1200,"price":3.29,"value":3948.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of May 15, 2019."}],"balance_after":3703,"source":{"system":"sec-edgar","filing":"0000899243-19-014050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319014050/doc4.xml","form_type":"4"}},{"id":3533462,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":8952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-26","expiration_date":"2028-02-26","underlying":"Ordinary Shares","underlying_shares":8952},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533461,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":6468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-01-06","expiration_date":"2027-01-06","underlying":"Ordinary Shares","underlying_shares":6468},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533460,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":7508,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":67000,"derivative":{"exercise_price":3.3667,"exercise_date":"2019-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":7508},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533459,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":139420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":139420},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533458,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":10457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2019-02-15","expiration_date":"2026-02-15","underlying":"Ordinary Shares","underlying_shares":10457},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533457,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":27924,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":0,"derivative":{"exercise_price":8.7901,"exercise_date":"2018-06-24","expiration_date":"2025-06-24","underlying":"Ordinary Shares","underlying_shares":27924},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533456,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":false,"shares":7,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":0,"derivative":{"exercise_price":0.0013,"exercise_date":"2018-06-24","expiration_date":"2025-06-24","underlying":"Ordinary Shares","underlying_shares":7},"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533455,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"sale","acquired":false,"shares":200736,"price":16.14,"value":3239879.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represented by ADSs. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The exercise price reported is price per ordinary share converted from price per ADS."}],"balance_after":2503,"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3533454,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2019-05-09T20:01:24.000Z","date":"2019-05-07","kind":"exercise","acquired":true,"shares":200736,"price":0.0013,"value":260.9568,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares (\"ADS\") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of May 7, 2019."}],"balance_after":203239,"source":{"system":"sec-edgar","filing":"0000899243-19-012933","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319012933/doc4.xml","form_type":"4"}},{"id":3611703,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:07:00.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":5988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":5988,"derivative":{"exercise_price":0.0013,"exercise_date":"2023-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":5988},"source":{"system":"sec-edgar","filing":"0000899243-19-006335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006335/doc4.xml","form_type":"4"}},{"id":3611702,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:07:00.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":5988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":5988,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":5988},"source":{"system":"sec-edgar","filing":"0000899243-19-006335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006335/doc4.xml","form_type":"4"}},{"id":3611701,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:07:00.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":5988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":5988,"derivative":{"exercise_price":0.0013,"exercise_date":"2021-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":5988},"source":{"system":"sec-edgar","filing":"0000899243-19-006335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006335/doc4.xml","form_type":"4"}},{"id":3611700,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:07:00.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":5988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":5988,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":5988},"source":{"system":"sec-edgar","filing":"0000899243-19-006335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006335/doc4.xml","form_type":"4"}},{"id":3611699,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:07:00.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":79812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":79812,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":79812},"source":{"system":"sec-edgar","filing":"0000899243-19-006335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006335/doc4.xml","form_type":"4"}},{"id":3611698,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":125520,"kind":"person","name":"Tovey Christopher J.","position":1,"cik":"0001754163","reported_name":"Tovey Christopher J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options","published_at":"2019-03-05T21:07:00.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":42048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"security","element":"securityTitle","label":"F2","text":"The reported options are options to purchase American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price reported is price per ordinary share converted from price per ADS ($172.01)."}],"balance_after":42048,"derivative":{"exercise_price":14.33,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":42048},"source":{"system":"sec-edgar","filing":"0000899243-19-006335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006335/doc4.xml","form_type":"4"}}]}